Announcement • Jun 18
ProtoKinetix, Incorporated Announces Management Changes
ProtoKinetix, Incorporated appointed Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified. Mr. Lamp and Mr. Jones are both seasoned entrepreneurs and longtime stockholders of the Company. Company had appointed Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified. Dr. Keith R. Brunt, age 47, is an Associate Professor of the Department of Pharmacology in the Faculty of Medicine at Dalhousie University; Adjunct Professor in the Faculty of Business at the University of New Brunswick; and a Translational Scientist at the New Brunswick Heart Centre. Dr. Brunt has served as a director and executive on several boards in both non-profit research organizations and for-profit companies, including as a director of Routinify Inc. from 2019-2024, and as the Chair of the Board of Directors of Heart & Stroke Foundation New Brunswick from 2021-2024. Dr. Brunt has extensive experience in the scientific and clinical research fields across several disciplines. As a specialist in translational science and medicine, Dr. Brunt has advanced degrees in Physiology (BSc. Hons.) from the University of Saskatchewan and a PhD in experimental medicine for gene and cell-based therapy from Queen's University in Kingston, ON, and has completed a Fellowship in regenerative medicine at the University Health Network in Toronto, ON. Dr. Brunt founded and, since 2014, has served as both a director and the Chief Scientific Officer of Nota Bene BioMatrix Inc., a knowledge brokerage, served as Director of Finance for IMPART, a research network, and directs an independent research program in the natural sciences and experimental therapeutics, where he has managed millions in research and development grants and commercialization funds, specializing in primordial molecules and their regulatory networks. Dr. Brunt has also served as a Medical Science Advisor to the Company since 2019. Dr. Brunt draws inspiration from nature and translates this excitement into innovation, maintaining a passion for improving quality of life through strategic research and development. On March 31, 2026, Mr. Edward McDonough, after serving many years as a trusted advisor to ProtoKinetix, Incorporated (the “Company”) under the leadership of Clarence E. Smith, notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective immediately. His decision to resign from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
